Evidence map›Paper›PMID 36812552›Full record

ArticlePLOS digital health2022

A pilot study of the Earable device to measure facial muscle and eye movement tasks among healthy volunteers.

Matthew F Wipperman, Galen Pogoncheff, Katrina F Mateo, Xuefang Wu, Yiziying Chen, Oren Levy, Andreja Avbersek, Robin R Deterding, Sara C Hamon, Tam Vu and 2 more

Abstract read
In one paragraph

Article in PLOS digital health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matthew F WippermanPrecision Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States of America.ORCID https://orcid.org/0000-0003-1436-3366
Galen PogoncheffEarable Inc., Boulder, Colorado, United States of America.ORCID https://orcid.org/0000-0001-6248-0992
Katrina F MateoClinical Outcomes Assessment and Patient Innovation, Global Clinical Trial Services, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States of America.ORCID https://orcid.org/0000-0003-3671-8893
Xuefang WuClinical Outcomes Assessment and Patient Innovation, Global Clinical Trial Services, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States of America.
Yiziying ChenBiostatistics and Data Management, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States of America.
Oren LevyEarly Clinical Development & Experimental Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States of America.ORCID https://orcid.org/0000-0002-9146-821X
Andreja AvbersekEarly Clinical Development & Experimental Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States of America.
Robin R DeterdingEarable Inc., Boulder, Colorado, United States of America.ORCID https://orcid.org/0000-0001-6890-3466
Sara C HamonPrecision Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States of America.ORCID https://orcid.org/0000-0002-2413-2302
Tam VuEarable Inc., Boulder, Colorado, United States of America.
Rinol AlajClinical Outcomes Assessment and Patient Innovation, Global Clinical Trial Services, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States of America.
Olivier HarariEarly Clinical Development & Experimental Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States of America.ORCID https://orcid.org/0000-0001-8214-489X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Earable device is a behind-the-ear wearable originally developed to measure cognitive function. Since Earable measures electroencephalography (EEG), electromyography (EMG), and electrooculography (EOG), it may also have the potential to objectively quantify facial muscle and eye movement activities relevant in the assessment of neuromuscular disorders. As an initial step to developing a digital assessment in neuromuscular disorders, a pilot study was conducted to determine whether the Earable device could be utilized to objectively measure facial muscle and eye movements intended to be representative of Performance Outcome Assessments, (PerfOs) with tasks designed to model clinical PerfOs, referred to as mock-PerfO activities. The specific aims of this study were: To determine whether the Earable raw EMG, EOG, and EEG signals could be processed to extract features describing these waveforms; To determine Earable feature data quality, test re-test reliability, and statistical properties; To determine whether features derived from Earable could be used to determine the difference between various facial muscle and eye movement activities; and, To determine what features and feature types are important for mock-PerfO activity level classification. A total of N = 10 healthy volunteers participated in the study. Each study participant performed 16 mock-PerfOs activities, including talking, chewing, swallowing, eye closure, gazing in different directions, puffing cheeks, chewing an apple, and making various facial expressions. Each activity was repeated four times in the morning and four times at night. A total of 161 summary features were extracted from the EEG, EMG, and EOG bio-sensor data. Feature vectors were used as input to machine learning models to classify the mock-PerfO activities, and model performance was evaluated on a held-out test set. Additionally, a convolutional neural network (CNN) was used to classify low-level representations of the raw bio-sensor data for each task, and model performance was correspondingly evaluated and compared directly to feature classification performance. The model's prediction accuracy on the Earable device's classification ability was quantitatively assessed. Study results indicate that Earable can potentially quantify different aspects of facial and eye movements and may be used to differentiate mock-PerfO activities. Specially, Earable was found to differentiate talking, chewing, and swallowing tasks from other tasks with observed F1 scores >0.9. While EMG features contribute to classification accuracy for all tasks, EOG features are important for classifying gaze tasks. Finally, we found that analysis with summary features outperformed a CNN for activity classification. We believe Earable may be used to measure cranial muscle activity relevant for neuromuscular disorder assessment. Classification performance of mock-PerfO activities with summary features enables a strategy for detecting disease-specific signals relative to controls, as well as the monitoring of intra-subject treatment responses. Further testing is needed to evaluate the Earable device in clinical populations and clinical development settings.

Identifiers

PMID36812552
PMCPMC9931353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.